<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335014">
  <stage>Registered</stage>
  <submitdate>13/01/2010</submitdate>
  <approvaldate>20/01/2010</approvaldate>
  <actrnumber>ACTRN12610000068066</actrnumber>
  <trial_identification>
    <studytitle>Mesenchymal Stromal Cells to Treat Steroid-refractory Graft Versus Host Disease after Bone Marrow Transplantation</studytitle>
    <scientifictitle>A phase 1 study to assess the safety of mesenchymal stromal cells to treat steroid-refractory graft versus host disease after allogeneic haemopoietic stem cell tranplantation.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Graft Versus Host Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Mesenchymal stromal cells 2 X 10E6/kg administered intrvenously over 15 minutes weekly for two weeks</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Other interventions</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety assessed clinically and by blood tests
weekly for 4 weeks, then monthly for 12 months after therapy</outcome>
      <timepoint>12 months after therapy finished, as assessed weekly for 4 weeks after therapy finished, then monthly to 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival as measured by actuarial survival from data linkage to medical records</outcome>
      <timepoint>12 months following completion of mesenchymal stromal cell therapy</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Age 18-60
Steroid-refractory graft versus host disease post allogeneic haemopoietic stem cell transplant
Informed consent given</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Discussion of risks, benefits, explanation of patient information document.
No allocation concealment, open label treatment</concealment>
    <sequence>N/A</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Mesenchymal cells may be Human Leucocyte Antigen (HLA) identical, haploidentical or third party</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/12/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>R.P.Herrmann</primarysponsorname>
    <primarysponsoraddress>Royal Perth Hospital
Wellington St
Perth 6000
Western Auistralia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Ray and Bill Dobney Trust</fundingname>
      <fundingaddress>Medical Research Foundation
Royal Perth Hospital 
Wellington St
Perth 6000
Western Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress>N/A</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Study hypothesis is that mesenchymal cells are safe and will be effective in treating steroid refractory graft versus host disease. Trial subjects will receive 2 X 10 E6/kg mesenchymal cells weekly for 2 weeks, are then reassessed weekly. If inadequate response may receive two further doses at weekly intervals. May be retreated if they subsequently relapse</summary>
    <trialwebsite />
    <publication>Mesenchymal Stromal Cells: A Transplant Tale. Australian Tissue Banking Forum May 2009, programme page 5.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>ethics committee, royal perth hospital</ethicname>
      <ethicaddress>Royal Perth Hospital
wellington St
Perth
Western Australia 6000</ethicaddress>
      <ethicapprovaldate>11/04/2007</ethicapprovaldate>
      <hrec>2007/090</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>r.p.herrmann</name>
      <address>Cell and Tissue Therapies W.A.
C/- Haematology Dept
Royal Perth Hospital
Wellington St
Perth 6000
Western Australia</address>
      <phone>+61 892243967</phone>
      <fax>+61892243449</fax>
      <email>richard.herrmann@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof R.P.Herrmann</name>
      <address>Cell and Tissue Therapies W.A.
C/- Haematology Dept
Royal Perth Hospital
Wellington St
Perth 6000
Western Australia</address>
      <phone>+61 892243967</phone>
      <fax>+61 892243449</fax>
      <email>richard.herrmann@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>r.p.herrmann</name>
      <address>Cell and Tissue Therapies W.A.
C/- Haematology Dept,
Royal Perth Hospital,
Wellington St,
Perth 6000
Western Australia</address>
      <phone>+61 892243967</phone>
      <fax>+61 892243449</fax>
      <email>richard.herrmann@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>